ProCE Banner Activity

MIRASOL: Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in FRα-High Expression, Platinum-Resistant Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Conference Coverage
Slideset

Mirvetuximab soravtansine significantly improved PFS and OS in patients with FRα-high, platinum-resistant advanced ovarian, primary peritoneal, or fallopian tube cancers compared with investigator’s choice of chemotherapy in this confirmatory phase III trial.

Released: June 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, GSK, and Merck Sharp & Dohme Corp.

AstraZeneca

GSK

Merck Sharp & Dohme Corp.